Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:MNPR NASDAQ:NRIX NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.60+2.9%$22.10$16.92▼$48.45$1.60B-0.059,674 shs11,877 shsMNPRMonopar Therapeutics$59.77+1.1%$58.62$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsNRIXNurix Therapeutics$16.95-0.2%$16.39$8.19▼$22.50$1.76B1.862.68 million shs2.56 million shsTYRATyra Biosciences$26.99+5.6%$33.68$8.98▼$40.65$1.52B0.75870,875 shs1.01 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.96%-6.40%-20.05%-29.96%-42.49%MNPRMonopar Therapeutics-0.54%-0.86%-3.67%-2.09%+70.56%NRIXNurix Therapeutics+10.98%+11.13%+6.39%+12.90%+34.44%TYRATyra Biosciences+0.59%-5.92%-26.67%-29.40%+151.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.60+2.9%$22.10$16.92▼$48.45$1.60B-0.059,674 shs11,877 shsMNPRMonopar Therapeutics$59.77+1.1%$58.62$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsNRIXNurix Therapeutics$16.95-0.2%$16.39$8.19▼$22.50$1.76B1.862.68 million shs2.56 million shsTYRATyra Biosciences$26.99+5.6%$33.68$8.98▼$40.65$1.52B0.75870,875 shs1.01 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.96%-6.40%-20.05%-29.96%-42.49%MNPRMonopar Therapeutics-0.54%-0.86%-3.67%-2.09%+70.56%NRIXNurix Therapeutics+10.98%+11.13%+6.39%+12.90%+34.44%TYRATyra Biosciences+0.59%-5.92%-26.67%-29.40%+151.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43162.01% UpsideMNPRMonopar Therapeutics 3.00Buy$107.9181.05% UpsideNRIXNurix Therapeutics 2.88Moderate Buy$32.1489.10% UpsideTYRATyra Biosciences 2.86Moderate Buy$46.0070.45% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, NRIX, AAPG, and TYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026TYRATyra Biosciences Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $42.006/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/9/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold$28.00 ➝ $25.006/8/2026NRIXNurix Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $45.006/8/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $34.006/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M20.14N/AN/A$2.04 per share8.69MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ANRIXNurix Therapeutics$83.98M20.93N/AN/A$5.29 per share3.21TYRATyra BiosciencesN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-411.37%-64.21%-48.44%7/9/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.18N/AN/AN/AN/A-42.66%-39.79%8/13/2026 (Estimated)Latest MNPR, NRIX, AAPG, and TYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/9/2026Q2 2026NRIXNurix Therapeutics-$0.73N/AN/AN/A$15.95 millionN/A5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/13/2026Q1 2026TYRATyra Biosciences-$0.60-$0.64-$0.04-$0.64N/AN/A4/8/2026Q1 2026NRIXNurix Therapeutics-$0.76-$0.79-$0.03-$0.79$14.25 million$6.25 million3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/A3/25/2026H2 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77MNPRMonopar TherapeuticsN/A56.0456.04NRIXNurix TherapeuticsN/A6.016.01TYRATyra BiosciencesN/A20.4920.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AMNPRMonopar Therapeutics1.83%NRIXNurix TherapeuticsN/ATYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AMNPRMonopar Therapeutics20.50%NRIXNurix Therapeutics6.70%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.33 millionN/AN/AMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionableTYRATyra Biosciences2059.47 million52.04 millionOptionableMNPR, NRIX, AAPG, and TYRA HeadlinesRecent News About These CompaniesIs Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?June 12 at 9:27 AM | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | insidermonkey.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYMay 21, 2026 | prnewswire.comWolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendationMay 20, 2026 | msn.comTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMay 17, 2026 | fool.comAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price MomentumMay 15, 2026 | finance.yahoo.comHot Picks: Cancer biotech stocks gain ground amid M&A activityMay 13, 2026 | bnnbloomberg.caBTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings ResultsMay 13, 2026 | marketbeat.comTyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsMay 13, 2026 | prnewswire.comTyra Biosciences to Participate in Upcoming Investor ConferencesMay 7, 2026 | prnewswire.comTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQTyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsApril 17, 2026 | prnewswire.comGuggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 16, 2026 | msn.comCanaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 7, 2026 | msn.comA Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial ProgressApril 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR, NRIX, AAPG, and TYRA Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.60 +0.49 (+2.86%) Closing price 04:00 PM EasternExtended Trading$17.73 +0.13 (+0.74%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Monopar Therapeutics NASDAQ:MNPR$59.77 +0.67 (+1.13%) Closing price 04:00 PM EasternExtended Trading$59.68 -0.09 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Nurix Therapeutics NASDAQ:NRIX$16.95 -0.03 (-0.18%) Closing price 04:00 PM EasternExtended Trading$17.07 +0.12 (+0.68%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Tyra Biosciences NASDAQ:TYRA$26.99 +1.42 (+5.55%) Closing price 04:00 PM EasternExtended Trading$27.04 +0.05 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
